vs

Side-by-side financial comparison of Atara Biotherapeutics, Inc. (ATRA) and Catalyst Bancorp, Inc. (CLST). Click either name above to swap in a different company.

Catalyst Bancorp, Inc. is the larger business by last-quarter revenue ($2.7M vs $1.6M, roughly 1.7× Atara Biotherapeutics, Inc.). On growth, Catalyst Bancorp, Inc. posted the faster year-over-year revenue change (1.4% vs -95.1%). Over the past eight quarters, Catalyst Bancorp, Inc.'s revenue compounded faster (12.6% CAGR vs -75.9%).

Atara Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing allogeneic T-cell immunotherapies for patients with unmet medical needs across oncology, autoimmune disease, and infectious disease indications. It operates primarily in North America, Europe, and Asia-Pacific, partnering with research institutions to advance its novel treatment pipeline.

Catalyst Bancorp, Inc. is a U.S.-based financial holding company that operates community banking subsidiaries. It provides a full range of retail and commercial banking products including checking and savings accounts, small business loans, residential mortgages, personal lending, and wealth management services, primarily serving local regional markets across the U.S. with a focus on individual consumers and small business clients.

ATRA vs CLST — Head-to-Head

Bigger by revenue
CLST
CLST
1.7× larger
CLST
$2.7M
$1.6M
ATRA
Growing faster (revenue YoY)
CLST
CLST
+96.5% gap
CLST
1.4%
-95.1%
ATRA
Faster 2-yr revenue CAGR
CLST
CLST
Annualised
CLST
12.6%
-75.9%
ATRA

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ATRA
ATRA
CLST
CLST
Revenue
$1.6M
$2.7M
Net Profit
$456.0K
Gross Margin
Operating Margin
20.8%
Net Margin
17.2%
Revenue YoY
-95.1%
1.4%
Net Profit YoY
73.2%
-27.2%
EPS (diluted)
$0.13

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ATRA
ATRA
CLST
CLST
Q4 25
$1.6M
$2.7M
Q3 25
$3.5M
$2.8M
Q2 25
$17.6M
$2.8M
Q1 25
$98.1M
$2.9M
Q4 24
$32.8M
$2.5M
Q3 24
$40.2M
$3.2M
Q2 24
$28.6M
$2.8M
Q1 24
$27.4M
$2.1M
Net Profit
ATRA
ATRA
CLST
CLST
Q4 25
$456.0K
Q3 25
$-4.3M
$489.0K
Q2 25
$2.4M
$521.0K
Q1 25
$38.0M
$586.0K
Q4 24
$-12.7M
$626.0K
Q3 24
$-21.9M
$447.0K
Q2 24
$-19.0M
$527.0K
Q1 24
$-31.8M
$-4.7M
Operating Margin
ATRA
ATRA
CLST
CLST
Q4 25
20.8%
Q3 25
-103.5%
21.7%
Q2 25
18.2%
22.5%
Q1 25
39.5%
24.7%
Q4 24
-37.3%
31.2%
Q3 24
-54.1%
17.6%
Q2 24
-63.7%
23.0%
Q1 24
-114.2%
-284.6%
Net Margin
ATRA
ATRA
CLST
CLST
Q4 25
17.2%
Q3 25
-124.6%
17.7%
Q2 25
13.6%
18.5%
Q1 25
38.7%
20.1%
Q4 24
-38.8%
25.3%
Q3 24
-54.5%
14.2%
Q2 24
-66.5%
18.7%
Q1 24
-116.1%
-224.0%
EPS (diluted)
ATRA
ATRA
CLST
CLST
Q4 25
$0.13
Q3 25
$-0.32
$0.13
Q2 25
$0.19
$0.14
Q1 25
$3.50
$0.16
Q4 24
$0.27
$0.13
Q3 24
$-2.93
$0.11
Q2 24
$-3.10
$0.13
Q1 24
$-5.65
$-1.15

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ATRA
ATRA
CLST
CLST
Cash + ST InvestmentsLiquidity on hand
$8.5M
$25.2M
Total DebtLower is stronger
$14.7M
Stockholders' EquityBook value
$-38.5M
$81.7M
Total Assets
$20.2M
$282.9M
Debt / EquityLower = less leverage
0.18×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ATRA
ATRA
CLST
CLST
Q4 25
$8.5M
$25.2M
Q3 25
$13.7M
$37.3M
Q2 25
$22.3M
$40.1M
Q1 25
$13.8M
$40.3M
Q4 24
$42.5M
$44.3M
Q3 24
$67.2M
$45.8M
Q2 24
$35.3M
$75.5M
Q1 24
$46.2M
$76.0M
Total Debt
ATRA
ATRA
CLST
CLST
Q4 25
$14.7M
Q3 25
$14.7M
Q2 25
Q1 25
Q4 24
$9.6M
Q3 24
$29.5M
Q2 24
$30.3M
Q1 24
$29.4M
Stockholders' Equity
ATRA
ATRA
CLST
CLST
Q4 25
$-38.5M
$81.7M
Q3 25
$-36.6M
$81.6M
Q2 25
$-35.0M
$80.8M
Q1 25
$-55.1M
$80.6M
Q4 24
$-97.3M
$80.2M
Q3 24
$-90.5M
$81.7M
Q2 24
$-110.9M
$81.0M
Q1 24
$-98.3M
$81.3M
Total Assets
ATRA
ATRA
CLST
CLST
Q4 25
$20.2M
$282.9M
Q3 25
$30.2M
$283.8M
Q2 25
$36.9M
$273.8M
Q1 25
$62.0M
$271.6M
Q4 24
$109.1M
$276.7M
Q3 24
$142.7M
$280.6M
Q2 24
$117.3M
$295.3M
Q1 24
$165.3M
$282.0M
Debt / Equity
ATRA
ATRA
CLST
CLST
Q4 25
0.18×
Q3 25
0.18×
Q2 25
Q1 25
Q4 24
0.12×
Q3 24
0.36×
Q2 24
0.37×
Q1 24
0.36×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ATRA
ATRA
CLST
CLST
Operating Cash FlowLast quarter
$-50.9M
$3.3M
Free Cash FlowOCF − Capex
$3.1M
FCF MarginFCF / Revenue
116.8%
Capex IntensityCapex / Revenue
0.0%
7.1%
Cash ConversionOCF / Net Profit
7.21×
TTM Free Cash FlowTrailing 4 quarters
$5.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ATRA
ATRA
CLST
CLST
Q4 25
$-50.9M
$3.3M
Q3 25
$-9.8M
$912.0K
Q2 25
$-7.3M
$1.2M
Q1 25
$-28.1M
$427.0K
Q4 24
$-24.5M
$3.2M
Q3 24
$-4.0M
$896.0K
Q2 24
$-10.6M
$1.4M
Q1 24
$-29.6M
$247.0K
Free Cash Flow
ATRA
ATRA
CLST
CLST
Q4 25
$3.1M
Q3 25
$827.0K
Q2 25
$1.1M
Q1 25
$361.0K
Q4 24
$-24.6M
$2.7M
Q3 24
$771.0K
Q2 24
$-10.7M
$1.2M
Q1 24
$-29.7M
$223.0K
FCF Margin
ATRA
ATRA
CLST
CLST
Q4 25
116.8%
Q3 25
29.9%
Q2 25
39.7%
Q1 25
12.4%
Q4 24
-75.0%
110.9%
Q3 24
24.5%
Q2 24
-37.3%
41.5%
Q1 24
-108.7%
10.7%
Capex Intensity
ATRA
ATRA
CLST
CLST
Q4 25
0.0%
7.1%
Q3 25
0.0%
3.1%
Q2 25
0.0%
1.2%
Q1 25
0.0%
2.3%
Q4 24
0.3%
17.4%
Q3 24
0.0%
4.0%
Q2 24
0.1%
8.0%
Q1 24
0.5%
1.1%
Cash Conversion
ATRA
ATRA
CLST
CLST
Q4 25
7.21×
Q3 25
1.87×
Q2 25
-3.07×
2.21×
Q1 25
-0.74×
0.73×
Q4 24
5.07×
Q3 24
2.00×
Q2 24
2.64×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons